Preclinical evidences suggest new treatment options for endocrine disorders: Pasireotide (SOM230) and Everolimus (RAD001).
Schmid
H A
HA
Department of Oncology, Novartis Institutes for BioMedical Research, Basel, Switzerland. herbert.schmid@novartis.com
D000818:Animals; D004700:Endocrine System Diseases / Q000188:drug therapy*; D000068338:Everolimus; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D009842:Oligopeptides / Q000627:therapeutic use*; D011494:Protein Kinases / Q000187:drug effects; D017481:Receptors, Somatostatin / Q000187:drug effects; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000627:therapeutic use; D013004:Somatostatin / Q000031:analogs & derivatives; D058570:TOR Serine-Threonine Kinases
D007166:Immunosuppressive Agents; D009842:Oligopeptides; D017481:Receptors, Somatostatin; D013004:Somatostatin; C517782:pasireotide; D000068338:Everolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D020123:Sirolimus